Analysts Offer Insights on Healthcare Companies: Invitae (NYSE: NVTA) and Haemonetics Corp. (NYSE: HAE)

By Austin Angelo

Analysts fell to the sidelines weighing in on Invitae (NYSE: NVTA) and Haemonetics Corp. (NYSE: HAE) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Invitae (NYSE: NVTA)

In a report released today, Raymond Myers from Benchmark Co. reiterated a Hold rating on Invitae (NYSE: NVTA), with a price target of $8.50. The company’s shares opened today at $8.

According to TipRanks.com, Myers is a 2-star analyst with an average return of 1.3% and a 37.5% success rate. Myers covers the Healthcare sector, focusing on stocks such as Staar Surgical Company, Foundation Medicine, and Chembio Diagnostics.

Invitae has an analyst consensus of Hold.

Haemonetics Corp. (NYSE: HAE)

In a report released today, Jan Wald from Benchmark Co. reiterated a Hold rating on Haemonetics Corp. (NYSE: HAE), with a price target of $34. The company’s shares opened today at $37.72, close to its 52-week high of $38.37.

Wald commented:

“We have increased our price target to $34 from $32.”

According to TipRanks.com, Wald is a 5-star analyst with an average return of 12.9% and a 67.5% success rate. Wald covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Cardiovascular Systems, and Staar Surgical Company.

Currently, the analyst consensus on Haemonetics Corp. is Moderate Buy and the average price target is $38, representing a 0.7% upside.

In a report released yesterday, BTIG also reiterated a Hold rating on the stock.